Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab - PubMed
5 hours ago
- #ustekinumab
- #JAK inhibitors
- #ulcerative colitis
- JAK inhibitors are effective for inducing remission in moderate-to-severe ulcerative colitis (UC) but have potential adverse effects like infections and cardiovascular events.
- A 'positive switch' from JAK inhibitors to biologics like ustekinumab may be considered to avoid long-term side effects, even if remission is maintained.
- Case 1: A 53-year-old man with steroid-dependent UC achieved mucosal healing with upadacitinib but switched to ustekinumab due to recurrent colds and safety concerns, maintaining remission for one year.
- Case 2: A 36-year-old woman with refractory UC achieved remission with filgotinib but switched to ustekinumab due to pregnancy plans, maintaining remission for one year.
- The cases suggest that a positive switch to ustekinumab can be a reasonable option for UC patients concerned about long-term JAK inhibitor safety.